Fosamprenavir sodium
Based on 3 publication(s) in Google Scholar
Fosamprenavir sodium is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir sodium is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir sodium can be used for the study of human immunodeficiency virus (HIV-1) infection.
For research use only. We do not sell to patients.
- CAS No.: 226700-80-7
- Formula: C25H34N3Na2O9PS
- Molecular Weight:629.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Fosamprenavir sodium
More
Biological Activity
Description
IC50 & Target
|
HIV-1 |
In Vitro
Amprenavir, the active form of Fosamprenavir sodium, can bind to and inhibit the activity of pepsin in vitro with an IC50 of 3.56 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-week-old female Jackson A/J mice with laryngopharyngeal reflux model (mechanical laryngeal injury once weekly for 2 weeks and pH7 solvent/pepsin instillation 3 days/week for 4 weeks)[2]
-
Dosage:20 mg/kg/day Fosamprenavir
-
Administration:gavage, daily, 4 weeks (5 days/week)
-
Result:Prevented pepsin-mediated laryngeal damage, which was characterized by reactive epithelia, increased intraepithelial inflammatory cells, and cell apoptosis.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 226700-80-7
-
Molecular Weight 629.57
-
Formula C25H34N3Na2O9PS
-
SMILES
O=C(O[C@H]1CCOC1)N[C@@H](CC2=CC=CC=C2)[C@H](OP(O[Na])(O[Na])=O)CN(CC(C)C)S(=O)(C3=CC=C(C=C3)N)=O
-
Synonyms
Amprenavir phosphate sodium; GW 433908 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. [Abstract]2020 Sep 4;11(1):4417. PMID: 32887884 -
Antimicrob Agents Chemother
2020 Aug 20;64(9):e00872-20. PMID: 32669265 -
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Hester EK, et al. Fosamprenavir: drug development for adherence. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1301-10. [Content Brief]
[2]. Johnston N, et al. Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model. Laryngoscope. 2023 Jan;133 Suppl 1(Suppl 1):S1-S11. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fosamprenavir sodium Related Classifications
HY-78726A Related Classifications
Powered by Bioz